Literature DB >> 22193759

Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS.

Hubert Dabiré1, Inès Barthélémy, Nicolas Blanchard-Gutton, Lucien Sambin, Carolina Carlos Sampedrano, Vassiliki Gouni, Yves Unterfinger, Pablo Aguilar, Jean-Laurent Thibaud, Bijan Ghaleh, Alain Bizé, Jean-Louis Pouchelon, Stéphane Blot, Alain Berdeaux, Luc Hittinger, Valérie Chetboul, Jin Bo Su.   

Abstract

Little is known about the vascular function and expression of endothelial and neuronal nitric oxide synthases (eNOS and nNOS) in Duchenne muscular dystrophy (DMD). Bradykinin is involved in the regulation of eNOS expression induced by angiotensin-converting enzyme inhibitors. We characterized the vascular function and eNOS and nNOS expression in a canine model of DMD and evaluated the effects of chronic bradykinin treatment. Vascular function was examined in conscious golden retriever muscular dystrophy (GRMD) dogs with left ventricular dysfunction (measured by echocardiography) and in isolated coronary arteries. eNOS and nNOS proteins in carotid arteries were measured by western blot and cyclic guanosine monophosphate (cGMP) content was analyzed by radioimmunoassay. Compared with controls, GRMD dogs had an impaired vasodilator response to acetylcholine. In isolated coronary artery, acetylcholine-elicited relaxation was nearly absent in placebo-treated GRMD dogs. This was explained by reduced nNOS and eNOS proteins and cGMP content in arterial tissues. Chronic bradykinin infusion (1 μg/min, 4 weeks) restored in vivo and in vitro vascular response to acetylcholine to the level of control dogs. This effect was NO-mediated through upregulation of eNOS and nNOS expression. In conclusion, this study is the first to demonstrate that DMD is associated with NO-mediated vascular endothelial dysfunction linked to an altered expression of eNOS and nNOS, which can be overcome by bradykinin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193759      PMCID: PMC3358670          DOI: 10.1007/s00395-011-0240-6

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  44 in total

1.  An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy.

Authors:  N J Sharp; J N Kornegay; S D Van Camp; M H Herbstreith; S L Secore; S Kettle; W Y Hung; C D Constantinou; M J Dykstra; A D Roses
Journal:  Genomics       Date:  1992-05       Impact factor: 5.736

Review 2.  The L-arginine-nitric oxide pathway.

Authors:  S Moncada; A Higgs
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

3.  Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure.

Authors:  F Barbe; J B Su; T T Guyene; B Crozatier; J Ménard; L Hittinger
Journal:  Am J Physiol       Date:  1996-06

4.  Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface.

Authors:  E Bonilla; C E Samitt; A F Miranda; A P Hays; G Salviati; S DiMauro; L M Kunkel; E P Hoffman; L P Rowland
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

5.  Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy.

Authors:  J E Brenman; D S Chao; H Xia; K Aldape; D S Bredt
Journal:  Cell       Date:  1995-09-08       Impact factor: 41.582

6.  Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide.

Authors:  T Ehring; D Baumgart; M Krajcar; M Hümmelgen; S Kompa; G Heusch
Journal:  Circulation       Date:  1994-09       Impact factor: 29.690

7.  Role of endogenous bradykinin in human coronary vasomotor control.

Authors:  P Groves; S Kurz; H Just; H Drexler
Journal:  Circulation       Date:  1995-12-15       Impact factor: 29.690

Review 8.  Nitric oxide in myocardial ischemia/reperfusion injury.

Authors:  Rainer Schulz; Malte Kelm; Gerd Heusch
Journal:  Cardiovasc Res       Date:  2004-02-15       Impact factor: 10.787

9.  Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies.

Authors:  B A Valentine; B J Cooper; A de Lahunta; R O'Quinn; J T Blue
Journal:  J Neurol Sci       Date:  1988-12       Impact factor: 3.181

10.  Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy.

Authors:  W J Chang; S T Iannaccone; K S Lau; B S Masters; T J McCabe; K McMillan; R C Padre; M J Spencer; J G Tidball; J T Stull
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

View more
  12 in total

1.  Calycosin and formononetin from astragalus root enhance dimethylarginine dimethylaminohydrolase 2 and nitric oxide synthase expressions in Madin Darby Canine Kidney II cells.

Authors:  Fan Bai; Toshiaki Makino; Keiko Kono; Akito Nagatsu; Takahiko Ono; Hajime Mizukami
Journal:  J Nat Med       Date:  2013-02-16       Impact factor: 2.343

2.  The hypertensive effect of sorafenib is abolished by sildenafil.

Authors:  Hubert Dabiré; Fatou Dramé; Nelly Cita; Bijan Ghaleh
Journal:  Cardiooncology       Date:  2020-07-13

3.  Neuronal nitric oxide synthase is indispensable for the cardiac adaptive effects of exercise.

Authors:  Steve R Roof; Lifei Tang; Joseph E Ostler; Muthu Periasamy; Sandor Györke; George E Billman; Mark T Ziolo
Journal:  Basic Res Cardiol       Date:  2013-02-04       Impact factor: 17.165

Review 4.  Vascular endothelial dysfunction and pharmacological treatment.

Authors:  Jin Bo Su
Journal:  World J Cardiol       Date:  2015-11-26

5.  Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy.

Authors:  Nazish Sayed; Chun Liu; Mohamed Ameen; Farhan Himmati; Joe Z Zhang; Saereh Khanamiri; Jan-Renier Moonen; Alexa Wnorowski; Linling Cheng; June-Wha Rhee; Sadhana Gaddam; Kevin C Wang; Karim Sallam; Jack H Boyd; Y Joseph Woo; Marlene Rabinovitch; Joseph C Wu
Journal:  Sci Transl Med       Date:  2020-07-29       Impact factor: 17.956

6.  Dystrophin deficiency impairs vascular structure and function in the canine model of Duchenne muscular dystrophy.

Authors:  Kasun Kodippili; Pamela K Thorne; M Harold Laughlin; Dongsheng Duan
Journal:  J Pathol       Date:  2021-06-14       Impact factor: 9.883

7.  Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering.

Authors:  Sara Martina Maffioletti; Shilpita Sarcar; Alexander B H Henderson; Ingra Mannhardt; Luca Pinton; Louise Anne Moyle; Heather Steele-Stallard; Ornella Cappellari; Kim E Wells; Giulia Ferrari; Jamie S Mitchell; Giulia E Tyzack; Vassilios N Kotiadis; Moustafa Khedr; Martina Ragazzi; Weixin Wang; Michael R Duchen; Rickie Patani; Peter S Zammit; Dominic J Wells; Thomas Eschenhagen; Francesco Saverio Tedesco
Journal:  Cell Rep       Date:  2018-04-17       Impact factor: 9.423

8.  Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.

Authors:  Zoe White; Nadia Milad; Arash Y Tehrani; William Wei-Han Chen; Graham Donen; Stephanie L Sellers; Pascal Bernatchez
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

9.  Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strategy approaches in muscular dystrophy.

Authors:  Ehsan Afzal; Saba Zakeri; Peyman Keyhanvar; Meisam Bagheri; Parvin Mahjoubi; Mahtab Asadian; Nogol Omoomi; Mohammad Dehqanian; Negar Ghalandarlaki; Tahmineh Darvishmohammadi; Fatemeh Farjadian; Mohammad Sadegh Golvajoee; Shadi Afzal; Maryam Ghaffari; Reza Ahangari Cohan; Amin Gravand; Mehdi Shafiee Ardestani
Journal:  Int J Nanomedicine       Date:  2013-08-08

10.  Effects of a novel ACE inhibitor, 3-(3-thienyl)-l-alanyl-ornithyl-proline, on endothelial vasodilation and hepatotoxicity in l-NAME-induced hypertensive rats.

Authors:  Mahesh Kumar Seth; M Ejaz Hussain; Santosh Pasha; Mohammad Fahim
Journal:  Drug Des Devel Ther       Date:  2016-04-20       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.